AIM ImmunoTech Files S-1/A Amendment

TL;DR

AIM ImmunoTech filed an S-1/A update on Feb 3, 2025, showing preferred stock and capital details.

AI Summary

AIM ImmunoTech Inc. filed an S-1/A amendment on February 3, 2025, detailing its financial structure. The filing includes information on Series A Junior Participating Preferred Stock and Series B Convertible Preferred Stock as of September 30, 2024, and December 31, 2023. It also references common stock and additional paid-in capital as of December 31, 2023.

Why It Matters

This filing provides updated financial details for AIM ImmunoTech Inc., which is crucial for investors to assess the company's capital structure and potential future offerings.

Risk Assessment

Risk Level: medium — S-1/A filings often indicate potential stock offerings or significant financial changes, which carry inherent investment risks.

Key Numbers

• 2024-09-30 — Reporting Period End (Financial data as of this date is detailed in the filing.)
• 2023-12-31 — Reporting Period End (Financial data as of this date is detailed in the filing.)

Key Players & Entities

• AIM ImmunoTech Inc. (company) — Filer of the S-1/A amendment
• February 3, 2025 (date) — Filing date of the S-1/A amendment
• September 30, 2024 (date) — Reporting date for financial data
• December 31, 2023 (date) — Reporting date for financial data

FAQ

Key Financial Figures

• $0.001 — of one share of common stock, par value $0.001 per share, one Class E warrant ("Class
• $0.2012 — at an assumed public offering price of $0.2012 per Unit for gross proceeds of approxim
• $10.0 million — nit for gross proceeds of approximately $10.0 million. The public offering price per Unit wil
• $0.2019 — on the American on January 31, 2025 was $0.2019 per share. We are not currently in comp
• $6,000,000 — ty is less than the required minimum of $6,000,000. Pursuant to the letter from the Exchan
• $2.9 million — 30, 2024, our stockholders' equity was $2.9 million. We must increase our stockholders' equ
• $6 million — our stockholders' equity to be at least $6 million to regain compliance with this rule. If
• $0 — luding one share of common stock, minus $0.001, and the exercise price of each Pre
• $9,034,000 — in this offering will be approximately $9,034,000, after deducting the placement agent fe

Filing Documents

• forms-1a.htm (S-1/A) — 4046KB
• ex1-1.htm (EX-1.1) — 137KB
• ex4-26.htm (EX-4.26) — 142KB
• ex4-27.htm (EX-4.27) — 125KB
• ex4-28.htm (EX-4.28) — 139KB
• ex5-1.htm (EX-5.1) — 18KB
• ex10-118.htm (EX-10.118) — 264KB
• ex10-119.htm (EX-10.119) — 34KB
• ex23-1.htm (EX-23.1) — 4KB
• ex107.htm (EX-FILING FEES) — 65KB
• forms-1a_001.jpg (GRAPHIC) — 19KB
• 0001493152-25-004609.txt ( ) — 16398KB
• aim-20240930.xsd (EX-101.SCH) — 81KB
• aim-20240930_cal.xml (EX-101.CAL) — 86KB
• aim-20240930_def.xml (EX-101.DEF) — 396KB
• aim-20240930_lab.xml (EX-101.LAB) — 607KB
• aim-20240930_pre.xml (EX-101.PRE) — 493KB
• forms-1a_htm.xml (XML) — 3064KB

RISK FACTORS

RISK FACTORS 7 CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND SUMMARY RISK FACTORS 20

USE OF PROCEEDS

USE OF PROCEEDS 22 CAPITALIZATION 23

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 25

BUSINESS

BUSINESS 35 MANAGEMENT 54 EXECUTIVE AND DIRECTOR COMPENSATION 57 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 64 PRINCIPAL STOCKHOLDERS 64

DESCRIPTION OF SECURITIES

DESCRIPTION OF SECURITIES 65 PLAN OF DISTRIBUTION 69 LEGAL MATTERS 75 EXPERTS 75 WHERE YOU CAN FIND MORE INFORMATION 75 i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus and in any free writing prospectus. We have not and the placement agent has not authorized anyone to provide you with information different from that contained in this prospectus. We are offering to sell, and seeking offers to buy, our securities only in jurisdictions where offers and sales are permitted. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our securities. Neither we nor the placement agent have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of our securities and the distribution of this prospectus outside of the United States. 1 PROSPECTUS SUMMARY This summary contains basic information about us and this offering. Because it is a summary, it does not contain all of the information that you should consider before investing. Before you decide to invest in our securities, you should read this entire prospectus carefully, including the section entitled "Risk Factors." Unless the context otherwise requires, references in this prospectus to "AIM," "the Company," "we," "us" and "our" refer to AIM ImmunoTech Inc. and our subsidiaries. Our

Business

Business AIM ImmunoTech Inc. and its subsidiaries are an immuno-pharma company headquartered in Ocala, Florida, and focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases and immune-deficiency disorders and to treat cancers for which there are currently inadequate or unmet therapies. We have established a strong foundation of laboratory, pre-clinical and clinical data with respect to the development of nucleic acids and natural interferon to enhance the natural antiviral defense system of the human body, and to aid the development of therapeutic products for the treatment of certain cancers and chronic diseases. Our flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA ("dsRNA") molecule being developed for globally important cancers, viral diseases and disorders of the immune system, with more than 100,000 intravenous doses in humans. NF-B activation in the tumor microenvironment has been shown to increase Tregs and have the potential to enhance cancer cell proliferation. Unlike natural pathogenic dsRNAs and poly IC which activate NF-B, Ampligen avoids significant activation of this pathway. Ampligen has not been approved by the Food and Drug Administration (the "FDA") or marketed in the United States, but is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome ("CFS"). We are currently proceeding primarily in four areas: Conducting clinical trials to evaluate the efficacy and safety of Ampligen for the treatment of pancreatic cancer. Evaluating Ampligen across multiple cancers as a potential therapy that modifies the tumor microenvironment with the goal of increasing anti-tumor responses to checkpoint inhibitors. Exploring Ampligen's antiviral activities and potential use as a prophylactic or treatment for existing viruses, new viruses and mutated viruses thereof. Evaluating Am

View Full Filing

View this S-1/A filing on SEC EDGAR